At ICPR 2024, we talked to Robert Jesse, from the Johns Hopkins University, about mystical experiences with psychedelics, their spiritual and cultural dimensions, and the value of community in supporting their responsible integration.

What actually makes psychedelic therapy work? Is it the drug, the therapeutic setting, or the human relationship between therapist and participant? At ICPR 2026, we spoke with psychiatrist and researcher Sandeep Nayak about clinical trials, common therapeutic factors, and how the field can better understand the mechanisms behind psychedelic-assisted treatment.

At ICPR 2024, we talked to anthropologist and author Nicolas Langlitz about the current hype around psychedelics, their place in medicine and culture, and why he sees them as holding the promise of moksha in the age of soma.

Women make up more than half of the population, yet they remain significantly underrepresented in psychedelic research. At ICPR 2026, we spoke with neuroscientist Grace Blest-Hopley about the gender gap in psychedelic science, the importance of studying menstrual cycles, pregnancy, menopause, and women’s mental health, and how the field can become more inclusive and scientifically rigorous.

Tadeusz Hawrot is the founder of the Psychedelic Access and Research European Alliance (PAREA), a Brussels-based initiative working to prepare Europe for the integration of psychedelic-assisted therapies into healthcare systems. In this interview, he reflects on the policy landscape, regulatory challenges, and the future of access to these emerging treatments in the EU.

With the new EU drug strategy now adopted, key questions remain about its direction and implementation—especially the balance between public health, human rights, and security. We spoke with Anna Dovbakh, Chair of the Civil Society Forum on Drugs, about what the strategy means in practice and the role of civil society moving forward.

As Hungary heads toward a pivotal election, the camera turns on two of its most prominent drug policy advocates. In this interview conducted by Arild Knutsen, Drugreporter founders Péter Sárosi and István Gábor Takács reflect on decades of activism—and explain why they are now taking their fight to the streets to challenge an increasingly repressive system.

After 15 years at the helm of the International Drug Policy Consortium, Ann Fordham is stepping down as Executive Director. Under her leadership, IDPC has grown into one of the most influential global networks advocating for drug policies grounded in human rights, public health, and social justice. In this interview, we reflect on IDPC’s achievements, ongoing challenges, and what lies ahead.

Jeremy Rudy, founder of the Sabba Collective, explains how psychedelic therapy can be integrated into society safely and responsibly — from education to policy.

Leor Roseman is a psychedelic researcher whose work explores both the individual and collective dimensions of psychedelic experience — from DMT interruption studies to intergroup healing in the Israeli-Palestinian context. In this interview, we discuss how psychedelics may open space not only for personal transformation, but also for collective reconciliation.